低胆固醇度和胃潰瘍出血的風險:一項回顧性對照研究
Mehmet Kök1, Süleyman Dolu2, Mehmet Emin Arayici3
1Department of Internal Medicine, University of Health Sciences, Antalya Training and Research Hospital, Antalya 07100, Turkey.
Journal of clinical medicine
|June 26, 2025
概括
低胆固醇水平,包括低密度脂蛋白胆固醇 (LDL-C) 和高密度脂蛋白胆固醇 (HDL-C),与胃潰瘍出血 (PUB) 的风险增加有关. 监测胃潰瘍患者的胆固醇可能有助于评估出血风险.
科学领域:
- 胃肠病学 胃肠病学
- 心血管医学 心血管医学
- 临床流行病学临床流行病学
背景情况:
- 低脂血是出血并发症的已知危险因素.
- 胃出血 (PUB) 是一个重大的临床挑战.
- 了解影响PUB风险的因素对于患者管理至关重要.
研究的目的:
- 为了研究血清胆固醇水平与胃潰瘍出血的发生率之间的联系.
- 为了确定特定的胆固醇分数 (TC,LDL-C,HDL-C) 是否与PUB风险相关.
- 为了确定潜在的胆固醇切断点来预测PUB.
主要方法:
- 追溯的队列研究,对317名通过食管胃肠透镜 (EGD) 诊断出胃的患者进行了追溯的队列研究.
- 测量血清胆固醇水平 (TC,LDL-C,HDL-C) 并计算累计平均度.
- 统计分析以比较出血和不出血的胃潰瘍群和对照群之间的胆固醇水平.
主要成果:
- 与非出血患者和对照患者相比,PUB患者的总胆固醇 (TC),LDL-C和HDL-C水平显著降低 (p < 0.001).
- 确定了最佳切线值:LDL-C为91.50 mg/dL (75.1%的灵敏度) 和HDL-C为42.50 mg/dL (72.3%的灵敏度).
- 每增加1个单位的LDL-C和HDL-C都与分别减少0.95倍和0.97倍的PUB风险有关.
结论:
- 降低胆固醇水平,特别是LDL-C和HDL-C,与胃出血的风险增加有关.
- 在胃潰瘍患者,尤其是高出血風險患者中,對膽固醇的監測可能是一個有價值的臨床策略.
- 进一步的研究可以探索将低脂血症与PUB联系在一起的机制,并完善风险分层模型.
更多相关视频
相关概念视频
01:30Peptic Ulcer Disease I: Introduction
302
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
302
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
209
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
209
01:28Peptic Ulcer Disease II: Pathophysiology
893
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
893
01:26Peptic Ulcer Disease IV: Management
150
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
150
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
728
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
728
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
604
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
604